Duke University Medical Centre in North Carolina USA is enrolling patients diagnosed with Autistic Spectrum Disorder in a phase one clinical trial involving infusion of their own cord blood stem cells.
At Biovault, we’ve released 3 umbilical cord blood samples to Duke University Medical Centre in the last 5 years to treat cerebral palsy, so we thought we’d keep you informed of this latest study.
The study aims to determine the safety of a single intravenous infusion of autologous (self) umbilical cord blood in paediatric patients with Autism. It also aims to determine which outcome measures best capture any impact these stem cell infusions might have on the child’s condition so those measures can be used in a future randomised phase II clinical trial.
Duke University’s criteria of consideration for inclusion in this study is as follows:
• Your child must have a confirmed diagnosis of Autistic Spectrum Disorder
• Your child must be between 24 months and 72 months of age.
• Your child must have his or her own cord blood stored and it must meet certain criteria for use.
• Must be able to travel to Duke University Medical Center in North Carolina, U.S.
Dr Joanna Tilley, Technical Director at Biovault Family, said: “We fully recognise that Biovault clients based outside of the USA might not be able to engage in this trial. However, we thought it would be useful to let you know that umbilical cord stem cells are being used in a study to tackle Autism – a disorder that affects millions of families worldwide. If you would like further information on this clinical trial please feel free to get in touch drop me an email at email@example.com”
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.